Wednesday, May 14
MS Therapy Tysabri (Natalizumab) Being Tested In New Clinical Trial
The drug, natalizumab (Tysabri), from Biogen Idec is currently in Phase 3b Clinical Trials. Officially titled “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension,” the trial is split into two parts. Part 1 is investigating if natalizumab slows the accumulation of disability not related to relapses relative to a placebo, and Part 2 is a continuation of the safety evaluation of natalizumab, where all participants may receive natalizumab. The trial began in July 2011 and is estimated to be completed in December 2014, with longer-term endpoints being collected for a total of approximately four years.